JP5740689B2 - タンパク質の経口投与用の方法および組成物 - Google Patents

タンパク質の経口投与用の方法および組成物 Download PDF

Info

Publication number
JP5740689B2
JP5740689B2 JP2011523481A JP2011523481A JP5740689B2 JP 5740689 B2 JP5740689 B2 JP 5740689B2 JP 2011523481 A JP2011523481 A JP 2011523481A JP 2011523481 A JP2011523481 A JP 2011523481A JP 5740689 B2 JP5740689 B2 JP 5740689B2
Authority
JP
Japan
Prior art keywords
another embodiment
insulin
amount
protein
snac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011523481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500254A5 (cg-RX-API-DMAC7.html
JP2012500254A (ja
Inventor
キドロン，ミリアム
アービット，エフド
Original Assignee
エンテラ バイオ エルティーディー．
エンテラ バイオ エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンテラ バイオ エルティーディー．, エンテラ バイオ エルティーディー． filed Critical エンテラ バイオ エルティーディー．
Publication of JP2012500254A publication Critical patent/JP2012500254A/ja
Publication of JP2012500254A5 publication Critical patent/JP2012500254A5/ja
Application granted granted Critical
Publication of JP5740689B2 publication Critical patent/JP5740689B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2011523481A 2008-08-18 2009-08-11 タンパク質の経口投与用の方法および組成物 Active JP5740689B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8981208P 2008-08-18 2008-08-18
US61/089,812 2008-08-18
PCT/IL2009/000786 WO2010020978A1 (en) 2008-08-18 2009-08-11 Methods and compositions for oral administration of proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015004509A Division JP5981575B2 (ja) 2008-08-18 2015-01-13 タンパク質の経口投与用の方法および組成物

Publications (3)

Publication Number Publication Date
JP2012500254A JP2012500254A (ja) 2012-01-05
JP2012500254A5 JP2012500254A5 (cg-RX-API-DMAC7.html) 2012-09-27
JP5740689B2 true JP5740689B2 (ja) 2015-06-24

Family

ID=41706898

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011523481A Active JP5740689B2 (ja) 2008-08-18 2009-08-11 タンパク質の経口投与用の方法および組成物
JP2015004509A Active JP5981575B2 (ja) 2008-08-18 2015-01-13 タンパク質の経口投与用の方法および組成物
JP2016102778A Active JP6124095B2 (ja) 2008-08-18 2016-05-23 タンパク質の経口投与用の方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015004509A Active JP5981575B2 (ja) 2008-08-18 2015-01-13 タンパク質の経口投与用の方法および組成物
JP2016102778A Active JP6124095B2 (ja) 2008-08-18 2016-05-23 タンパク質の経口投与用の方法および組成物

Country Status (11)

Country Link
US (6) US9186412B2 (cg-RX-API-DMAC7.html)
EP (2) EP3741359A1 (cg-RX-API-DMAC7.html)
JP (3) JP5740689B2 (cg-RX-API-DMAC7.html)
CN (1) CN102123697B (cg-RX-API-DMAC7.html)
AU (1) AU2009283821B2 (cg-RX-API-DMAC7.html)
CA (1) CA2734442C (cg-RX-API-DMAC7.html)
ES (1) ES2823233T3 (cg-RX-API-DMAC7.html)
HK (1) HK1214153A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ591497A (cg-RX-API-DMAC7.html)
RU (2) RU2494755C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010020978A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015107990A (ja) * 2008-08-18 2015-06-11 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5222727B2 (ja) * 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
CA2719272C (en) 2008-03-26 2020-08-18 Oramed Ltd. Methods and compositions for oral administration of proteins
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MX2013000314A (es) 2010-07-09 2013-01-29 Affibody Ab Polipeptidos.
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MY161450A (en) 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
WO2013102899A1 (en) * 2012-01-03 2013-07-11 Oramed Ltd. Methods and compositions for treating diabetes
US10342764B2 (en) 2012-02-01 2019-07-09 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP4324475A1 (en) * 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
EP2827845B1 (en) * 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
KR102266299B1 (ko) * 2012-03-22 2021-06-18 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
EP2830665A1 (en) * 2012-03-28 2015-02-04 Affibody AB Oral administration
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CN111763247B (zh) 2012-09-25 2024-09-13 阿菲博迪公司 白蛋白结合多肽
EP2941267B1 (en) * 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
PL2991671T3 (pl) 2013-05-02 2019-01-31 Novo Nordisk As Doustne dawkowanie związków glp-1
CN104707131A (zh) * 2013-12-13 2015-06-17 上海建华精细生物制品有限公司 一种药物组合物及其制备方法和用途
WO2015091957A1 (en) 2013-12-20 2015-06-25 Affibody Ab Engineered albumin binding polypeptide
IL285440B1 (en) 2014-12-10 2025-09-01 Amryt Endo Inc Oral preparations containing octreotide in combination with other medicinal substances for the treatment of acromegaly
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN107205949A (zh) * 2015-01-29 2017-09-26 诺和诺德股份有限公司 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物
EP4527456A3 (en) 2015-02-03 2025-05-21 Amryt Endo, Inc. Treating acromegaly with oral octreotide
WO2016128970A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of hypoparathyroidism
ES2784703T3 (es) 2015-07-08 2020-09-30 Research & Business Found Sungkyunkwan Univ Derivados de la pirrolidina carboxamida y métodos para preparar y utilizar la misma
US20170189363A1 (en) * 2015-12-30 2017-07-06 Noven Pharmaceuticals, Inc. Gastric acid modulators for oral delivery of peptides and proteins
EP3445356B1 (en) 2016-04-22 2021-06-30 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EP3500291A4 (en) 2016-08-17 2020-03-11 Entera Bio Ltd. FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
EA201892396A1 (ru) * 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20180271792A1 (en) * 2017-03-23 2018-09-27 Rezolute, Inc. Oral delivery of physiologically active substances
CN108653233A (zh) * 2017-04-01 2018-10-16 苏州苏融生物医药有限公司 一种具有生物粘附性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途
CN108653719A (zh) * 2017-04-01 2018-10-16 苏州苏融生物医药有限公司 一种具有粘液穿透性载多肽蛋白类药物固体颗粒物、包含其的制剂、制备方法及用途
CN108653234B (zh) * 2017-04-01 2021-02-26 中国科学院上海药物研究所 载有多肽蛋白类药物的固体颗粒物及包含该颗粒物的双肠溶固体制剂、其制备方法及用途
WO2019042247A1 (zh) * 2017-08-28 2019-03-07 江苏恒瑞医药股份有限公司 一种cyp17抑制剂的药物组合物及其制备方法
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN109260464B (zh) * 2018-10-29 2021-10-15 兆科药业（合肥）有限公司 抗血小板溶栓素的新用途
MX2021005807A (es) 2018-11-19 2021-07-02 Receptor Holdings Inc Aminoacidos grasos n-acilados para reducir la variabilidad de absorcion en composiciones basadas en cannabinoides.
JP7610410B2 (ja) * 2019-03-08 2025-01-08 アニヤ バイオファーム インク． 副甲状腺ホルモンアナログの経口製剤および治療
EP4025192B1 (en) 2019-09-02 2025-12-03 Novo Nordisk A/S Process for producing a tablet comprising glp-1 peptides
EP4025240B1 (en) * 2019-09-03 2024-10-30 Amgen Inc. Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN115209910A (zh) * 2020-03-18 2022-10-18 四川海思科制药有限公司 口服药物组合物
CN115461044B (zh) 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
CN111909955B (zh) * 2020-08-10 2021-12-31 安徽新熙盟生物科技有限公司 重组MANNase-GLP-1及同源物的制备及应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
JP2024525377A (ja) 2021-07-15 2024-07-12 ノヴォ ノルディスク アー／エス Ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む錠剤
KR20240063870A (ko) 2021-08-23 2024-05-10 유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이. 캡슐화된 생활성 거대분자를 갖는 리오트로픽 액정성 나노시스템

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5426616A (en) 1977-07-30 1979-02-28 Fujitsu Ltd Input level monitor system for level adjuster and automatic restoration system for level adjuster
JPS5740689A (en) 1980-08-25 1982-03-06 Tokyo Shibaura Electric Co Nuclear reactor shutdown device
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS60224638A (ja) * 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
AU712222B2 (en) * 1995-03-31 1999-11-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
WO1998005351A1 (en) * 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
EP1397156B1 (en) * 2001-06-01 2007-03-14 Novartis AG Oral administration of parathyroid hormone and calcitonin
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
ES2465496T3 (es) * 2003-01-06 2014-06-05 Emisphere Technologies, Inc. Terapia de insulina oral nocturna
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
EP1643978A1 (en) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
PL1651249T3 (pl) * 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
JP2005281231A (ja) * 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
JP2007532629A (ja) * 2004-04-15 2007-11-15 キアスマ， インコーポレイテッド 生物学的障壁を横切る透過を促進し得る組成物
JP2007536268A (ja) 2004-05-06 2007-12-13 エミスフェアー・テクノロジーズ・インク 固体剤形の湿性ヘパリン
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
EP1843755B1 (en) * 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
WO2006103657A2 (en) 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2538254T3 (es) * 2006-04-18 2015-06-18 Emisphere Technologies, Inc. Agentes de administración de dialquil éter
NZ591497A (en) * 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015107990A (ja) * 2008-08-18 2015-06-11 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
JP2016185970A (ja) * 2008-08-18 2016-10-27 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
US10010503B2 (en) 2008-08-18 2018-07-03 Entera Bio Ltd. Methods and compositions for oral administration
US10420721B2 (en) 2008-08-18 2019-09-24 Entera Bio Ltd. Methods and compositions for oral administration
US11246827B2 (en) 2008-08-18 2022-02-15 Entera Bio Ltd. Methods and compositions for oral administration
US12311051B2 (en) 2008-08-18 2025-05-27 Entera Bio Ltd. Methods and compositions for oral administration

Also Published As

Publication number Publication date
US12311051B2 (en) 2025-05-27
US9186412B2 (en) 2015-11-17
US20190380953A1 (en) 2019-12-19
CA2734442C (en) 2016-08-16
EP3741359A1 (en) 2020-11-25
EP2331072B1 (en) 2020-07-22
JP2012500254A (ja) 2012-01-05
EP2331072B8 (en) 2020-08-26
ES2823233T3 (es) 2021-05-06
US20250281396A1 (en) 2025-09-11
CA2734442A1 (en) 2010-02-25
RU2011108334A (ru) 2012-09-27
US20160058699A1 (en) 2016-03-03
JP2016185970A (ja) 2016-10-27
RU2494755C2 (ru) 2013-10-10
AU2009283821B2 (en) 2014-05-29
JP5981575B2 (ja) 2016-08-31
HK1214153A1 (zh) 2016-09-02
RU2013130611A (ru) 2015-01-10
JP2015107990A (ja) 2015-06-11
RU2646828C2 (ru) 2018-03-07
WO2010020978A1 (en) 2010-02-25
EP2331072A4 (en) 2013-12-18
US20220151919A1 (en) 2022-05-19
CN102123697A (zh) 2011-07-13
US11246827B2 (en) 2022-02-15
AU2009283821A1 (en) 2010-02-25
NZ591497A (en) 2012-11-30
US10010503B2 (en) 2018-07-03
EP2331072A1 (en) 2011-06-15
JP6124095B2 (ja) 2017-05-10
US10420721B2 (en) 2019-09-24
US20180280292A1 (en) 2018-10-04
CN102123697B (zh) 2015-06-10
US20110142800A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
JP6124095B2 (ja) タンパク質の経口投与用の方法および組成物
JP5395160B2 (ja) タンパク質の経口投与方法及び組成物
AU2015243030B2 (en) Methods and compositions for oral administration of proteins
CN104857505A (zh) 用于口服给予蛋白质的方法和组合物
AU2014218446B2 (en) Methods and compositions for oral administration of proteins
HK40039520A (en) Methods and compositions for oral administration of proteins
AU2013237663B2 (en) Methods and compositions for oral administration of proteins
HK1158938B (en) Methods and compositions for oral administration of proteins
HK1158938A (en) Methods and compositions for oral administration of proteins

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150406

R150 Certificate of patent or registration of utility model

Ref document number: 5740689

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250